• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Improving the efficacy of peptide vaccines in cancer immunotherapy
Int Immunopharmacol. 2023 Aug 3;123:110721. doi: 10.1016/j.intimp.2023.110721. Online ahead of print.ABSTRACTPeptide vaccines have shown great potential in cancer immunotherapy by targeting tumor antigens and activating the patient's immune system to mount a specific response against cancer cells. However, the efficacy of peptide vaccines in inducing a sustained immune response and achieving clinical benefit remains a major challenge. In this review, we discuss the current status of peptide vaccines in cancer immunotherapy and strategies to improve their efficacy. We summarize the recent advancements in the development of ...
Source: International Immunopharmacology - August 5, 2023 Category: Allergy & Immunology Authors: Fatemeh Zahedipour Khadijeh Jamialahmadi Parvin Zamani Mahmoud Reza Jaafari Source Type: research

Breast cancer vaccination: Latest advances with an analytical focus on clinical trials
Int Immunopharmacol. 2023 Jul 24;123:110696. doi: 10.1016/j.intimp.2023.110696. Online ahead of print.ABSTRACTBreast cancer (BC) is one of the main causes of cancer-related death worldwide. The heterogenicity of breast tumors and the presence of tumor resistance, metastasis, and disease recurrence make BC a challenging malignancy. A new age in cancer treatment is being ushered in by the enormous success of cancer immunotherapy, and therapeutic cancer vaccination is one such area of research. Nevertheless, it has been shown that the application of cancer vaccines in BC as monotherapy could not induce satisfying anti-tumor i...
Source: International Immunopharmacology - July 26, 2023 Category: Allergy & Immunology Authors: Mahdi Kohansal Vajari Mohammad-Javad Sanaei Sina Salari Alireza Rezvani Mehrnaz Sadat Ravari Davood Bashash Source Type: research

Dual anti-PD-(L)1/TGF- β inhibitors in cancer immunotherapy - Updated
Int Immunopharmacol. 2023 Jul 15;122:110648. doi: 10.1016/j.intimp.2023.110648. Online ahead of print.ABSTRACTImmune checkpoint inhibitor (ICI) therapy suffers from tumor resistance and relapse in majority of patients due to the suppressive tumor immune microenvironment (TIME). Advances in the field have brought about development of fusion proteins able to target two signaling simultaneously and to exert maximal anti-cancer immunity. Bispecific inhibitors of transforming growth factor (TGF)-β signaling and programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are developed to reduce the rate of relapse and to ach...
Source: International Immunopharmacology - July 17, 2023 Category: Allergy & Immunology Authors: Zana Karami Keywan Mortezaee Jamal Majidpoor Source Type: research

Immunogenicity after two and three doses of mRNA vaccine in patients with cancer treated with exclusive radiotherapy
CONCLUSION: In patients treated with exclusive RT, even during the Omicron breakthrough, robust humoral response and clinical protection from severe SARS-CoV-2 disease were achievable with three doses of mRNA vaccine.PMID:37392566 | DOI:10.1016/j.intimp.2023.110460
Source: International Immunopharmacology - July 1, 2023 Category: Allergy & Immunology Authors: Silvia Scoccianti Camilla Delli Paoli Maria Infantino Lisa Paoletti Saverio Caini Fiammetta Meacci Serenella Russo Marco Esposito Simona Fondelli Barbara Grilli Leonulli Valentina Grossi Raffaella Barca Paolo Alpi Federica Furlan Marco Perna Maria Simona Source Type: research

Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer
In this study, we reported that colon cancer cells treated with aspirin showed the hallmarks of immunogenic cell death (ICD), including surface expression of calreticulin (CRT) and heat shock protein 70 (HSP70). Mechanistically, aspirin induced endoplasmic reticulum (ER) stress in colon cancer cells. In addition, aspirin decreased the expression of the glucose transporters, GLUT3, and reduced the key enzyme of glycolysis, including HK2, PFKM, PKM2 and LDHA. The changes of tumor glycolysis after aspirin treatment were associated with c-MYC downregulation. Moreover, aspirin potentiated the antitumor efficacy of anti-PD-1 ant...
Source: International Immunopharmacology - June 8, 2023 Category: Allergy & Immunology Authors: Jun Lei Zihao Zhou Jialing Fang Zaiqiao Sun Mengting He Boxiao He Qian Chen Chonil Paek Peng Chen Jin Zhou Hongjian Wang Mingliang Tang Lei Yin Yongshun Chen Source Type: research

Production of monoclonal antibodies for therapeutic purposes: A review
Int Immunopharmacol. 2023 May 25;120:110376. doi: 10.1016/j.intimp.2023.110376. Online ahead of print.ABSTRACTMonoclonal antibodies (mAbs) have been used in the development of immunotherapies that target a variety of diseases, such as cancer, autoimmune diseases, and even viral infections; they play a key role in immunization and are expected after vaccination. However, some conditions do not promote the development of neutralizing antibodies. Production and use of mAbs, generated in biofactories, represent vast potential as aids in immunological responses when the organism cannot produce them on their own, these convey un...
Source: International Immunopharmacology - May 27, 2023 Category: Allergy & Immunology Authors: Waller-Pulido Alejandra Jim énez-Pérez Miriam Irene Gonzalez-Sanchez Fabio Antonio Rojo-Gutierrez Rocio Patricia Torres-Anguiano Elizabeth Aleman-Aguilar Juan Pablo Garcia-Varela Rebeca Source Type: research

Promoting immunity with novel targeting antigen delivery vehicle based on bispecific nanobody
In conclusion, our results demonstrate the potential of bispecific nanobody as a novel and efficient DC-specific antigen delivery vehicle. This highlights the potential to expand targeted delivery to the field of animal epidemic diseases and provides a reference for the general application of nanotechnology in viral diseases.PMID:37116343 | DOI:10.1016/j.intimp.2023.110140
Source: International Immunopharmacology - April 28, 2023 Category: Allergy & Immunology Authors: Haiwei Cheng Li Yang Liting Hou Zizheng Cai Xiaoming Yu Luping Du Jin Chen Qisheng Zheng Source Type: research

Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction
This article's main highlight is discussing the drug targets of SUDs and their associated mechanisms. Importantly, we have also discussed the scope of prophylactic measures to eliminate drug dependence.PMID:37099943 | DOI:10.1016/j.intimp.2023.110210
Source: International Immunopharmacology - April 26, 2023 Category: Allergy & Immunology Authors: Jonaid Ahmad Malik Javed N Agrewala Source Type: research

History of the discovery and development of Biomodulina T (InmunyVital ®), a useful immunomodulator with a broad range of clinical applications
This article identifies the milestones involved in the development of Biomodulina T. Since its discovery more than 35 years ago, reports show that Biomodulina T is a modulator of immune response and inflammation that is very useful for restoring the immune system in young and elderly people with immunodeficiencies, autoimmune diseases, and infections. Biomodulina T is also useful as an immunotherapeutic agent for improving immune responses in cancer and vaccines, for reversing immunosenescence and for improving healthspan in aging.PMID:37086680 | DOI:10.1016/j.intimp.2023.110167
Source: International Immunopharmacology - April 22, 2023 Category: Allergy & Immunology Authors: Roman R Rodriguez Martin Olivia Gonzalez Gonzalez Carolina Rodriguez Gonzalez Rene R Rodriguez Gonzalez Source Type: research

Pages: 1  2  3  4  5